D. E. Shaw & Co., Inc. Theseus Pharmaceuticals, Inc. Call Options Transaction History

D. E. Shaw & Co., Inc.

  • $107 Billion
  • Q3 2024

Call Options

0 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
No transaction found.

Others Institutions Holding THRX

# of Institutions
2
Shares Held
1.03M
Call Options Held
0
Put Options Held
0
View Full List

About Theseus Pharmaceuticals, Inc.

THRX Quotes by TradingView
  • Ticker THRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,713,400
  • Description
  • Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also ...
More about THRX
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email